References
- Sánchez-García I, Grütz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92: 5287–5291.
- Roszkiewicz F, Garidi R, Vaida I, . Tyrosine kinase inhibitors and solid tumours: case report and review of the literature. Pharmacology 2009;84:38–41.
- Buchdunger E, Zimmermann J, Mett H, . Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995;92:2558–2562.
- Paydas S, Duman BB, Ergin M. Non-Hodgkin's lymphoma developing in a case with chronic myelocytic leukemia. Turk J Hematol 2011;28:232–234.
- Heinrich MC, Griffith DJ, Druker BJ, . Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–932.
- Okuda K, Weisberg E, Gilliland DG, . ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440–2448.
- Summary of product characteristics of imatinib. 2007. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/glivec/H-406-PI-en.pdf
- Roy L, Guilhot J, Martineau G, . Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005;19:1689–1692.
- Piccin A, Conneally E, Lynch M, . Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. Leuk Lymphoma 2006;47:1394–1396.
- Tokuhara M, Gouda Y, Saito Y, . Gastrointestinal stromal tumor (GIST) that showed double new malignancies during imatinib therapy: a case report. J Clin Oncol 2008;26(Suppl.): Abstract 21517.
- Kalender ME, Sevinc A, Kucukdurmaz Z, . Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor. Onkologie 2007;30:568–570.
- Verma D, Kantarjian H, Strom SS, . Malignancies occurring during therapy with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353–4358.
- Pilot PR, Sablinska K, Owen S, . Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006;20:148; author reply 149.